Compare Adaptive Biotechnologies Corp (ADPT) vs Vanguard Total World Stock Index Fund ETF (VT) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Vanguard Total World Stock Index Fund ETF — how do they compare? Adaptive Biotechnologies Corp trades at $20.25 (market cap $3.33B), while Vanguard Total World Stock Index Fund ETF trades at $155.71. Which is the better fit depends on your goals.
| ADPT | VT | |
|---|---|---|
Market Cap | $3.33B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $22.37 | $159.35 |
52-Week Low | $10.24 | $128.41 |
Enterprise Value | $3.19B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
Vanguard Total World Stock ETF (VT) trades at $157.81, up 1.05% with a bullish technical signal from moving averages. The ETF shows neutral oscillator readings but faces overbought conditions on short-term RSI. Recent news highlights VT's global diversification advantages with over 10,000 holdings, though competitors offer lower expense ratios.
VT provides comprehensive global equity exposure but lacks available fundamental ratios in current data. The ETF's 1.6% dividend yield and broad diversification support long-term positioning, though expense ratio comparisons with peers like SCHF (0.03%) present competitive considerations for cost-conscious investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Vanguard Total World Stock Index Fund ETF
VT is a foundational, low-cost ETF that seeks to track the FTSE Global All Cap Index, providing exposure to nearly 10,000 stocks across developed and emerging markets worldwide, including the United States. It serves as a single-ticker solution for total global equity diversification, capturing approximately 98% of the world's investable market capitalization.
Read more on VT →
